Real Endpoints recently conducted research that found significant variability in treatment preferences among multiple sclerosis patients, as well as a difference in how patients define value in MS therapies compared to payers and physicians.
According to their research, for MS patients, providing greater opportunity for successful management of the disease and its progression requires the availability of a broad range of therapeutic alternatives.
Additionally, different patients may require different treatments depending on their preferences or treatment goals – some patients may place more weight on slowing disease progression, while others may be concerned about safety and side effect profiles.
Real Endpoints is a data and analytics firm.
Key findings from Real Endpoints’ research include that MS patients define value differently than payers and physicians and patients are more concerned about a medicine’s safety characteristics than payers or physicians.
Also, patients are more concerned with out-of-pocket costs than payers, who are primarily concerned about the medicine’s effect on health care services needed to treat multiple sclerosis.
